|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Likewise, in competitive tumor engraftment assays where we injected a 50:50 mixture of control and shPODXL (short-hairpin RNA targeting PODXL)-expressing cells, we found that podocalyxin-deficient cells exhibited a striking decrease in the ability to form clonal tumors in the lung, liver and bone marrow.
|
25887862 |
2015 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
These results implicate PODXL as a candidate prostate cancer tumor aggressiveness gene mapping to chromosome 7q32-q33.
|
16434482 |
2006 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Podocalyxin expression in malignant astrocytic tumors.
|
18639524 |
2008 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
The aim of this study was to clarify the role of PODXL overexpression in EMT in lung cancer, and to determine the prognostic value of PODXL overexpression in tumors from lung cancer patients.
|
28004467 |
2017 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
PODXL protein expression was analyzed by immunohistochemistry in tissue microarrays with tumour samples from a consecutive, retrospective cohort of 270 CRC patients (cohort 1) and a prospective cohort of 337 CRC patients (cohort 2).
|
22769594 |
2012 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
Protein sequence data obtained from purified podocalyxin protein isolated from embryonal carcinoma cancer stem cells reveals peptide sequence data for the glucose-3-transporter.
|
20599725 |
2010 |
|
Primary malignant neoplasm
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Disease free survival and cancer-specific survival were significantly worse for patients whose tumors overexpressed PODXL.
|
28004467 |
2017 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
This report identifies DNA methylation, miR-199a dysregulation and PODXL as critical factors in tumor malignancy.
|
21383689 |
2011 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
Podocalyxin is an anti-adhesive mucin-like transmembrane sialoglycoprotein that has been implicated in the development of aggressive forms of cancer.
|
18639524 |
2008 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
The cell-adhesion glycoprotein PODXL is associated with an aggressive tumor phenotype in several forms of cancer.
|
27461278 |
2016 |
|
Primary malignant neoplasm
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Array expression meta-analysis of cancer stem cell genes identifies upregulation of PODXL especially in DCC low expression meningiomas.
|
31083655 |
2019 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
Moreover, PODXL plays a critical role in cancer stemness, invasiveness, and sensitivity to chemotherapies in colon cancer HCT15 cells.
|
28946619 |
2017 |
|
Primary malignant neoplasm
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical analysis of PODXL showed that the expression of PODXL protein in cancer tissues is higher than that in adjacent tissues.
|
31669641 |
2020 |
|
Primary malignant neoplasm
|
0.090 |
AlteredExpression
|
group |
BEFREE |
These observations suggest that PCLP1 expression could provide a mechanism to evade the immune response, thereby promoting metastatic progression of cancer.
|
26276714 |
2015 |
|
Renal glomerular disease
|
0.040 |
Biomarker
|
group |
BEFREE |
Urinary podocalyxin is used as a marker for glomerular disease.
|
29321582 |
2018 |
|
Renal glomerular disease
|
0.040 |
Biomarker
|
group |
BEFREE |
Glomerular epithelial protein 1 and podocalyxin-like protein 1 in inflammatory glomerular disease (crescentic nephritis) in rabbit and man.
|
8600307 |
1996 |
|
Renal glomerular disease
|
0.040 |
AlteredExpression
|
group |
BEFREE |
In this study, we counted the numbers of podocyte in urine by our improved method and detected the PCX levels in urine by enzyme-linked immunosorbent assay (ELISA) in glomerulopathy patients and healthy controls.
|
27435507 |
2017 |
|
Renal glomerular disease
|
0.040 |
Biomarker
|
group |
BEFREE |
Urine markers of podocyte dysfunction: a review of podocalyxin and nephrin in selected glomerular diseases.
|
29976076 |
2018 |
|
Mammary Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Therefore, we set out to determine if podocalyxin plays a functional role in breast tumor progression.
|
26796961 |
2016 |
|
Mammary Neoplasms
|
0.040 |
AlteredExpression
|
group |
LHGDN |
Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression.
|
15289306 |
2004 |
|
Mammary Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Podocalyxin enhances breast tumor growth and metastasis and is a target for monoclonal antibody therapy.
|
25887862 |
2015 |
|
Mammary Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
PCLP1 increases breast tumor growth, migration and invasion; however, its role in hematologic malignancies still remains undetermined.
|
29245936 |
2017 |
|
Adenocarcinoma
|
0.030 |
AlteredExpression
|
group |
BEFREE |
In lung adenocarcinoma clinical specimens, PODXL expression was detected in minimally invasive and invasive adenocarcinoma, but not in non-invasive adenocarcinoma.
|
28004467 |
2017 |
|
Adenocarcinoma
|
0.030 |
AlteredExpression
|
group |
LHGDN |
Adenocarcinomas of the lung and prostate, and liver metastases of colorectal carcinomas lacked PODXL-1 expression.
|
17137615 |
2007 |
|
Adenocarcinoma
|
0.030 |
Biomarker
|
group |
BEFREE |
Here, we investigate the role of podocalyxin in migration and metastasis of pancreatic adenocarcinomas using SW1990 and Pa03c as cell models.
|
30975647 |
2019 |